Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma

BACKGROUND: Most cutaneous squamous cell carcinomas (CSCCs) can be treated with surgical excision or radiation; however, approximately 1% of patients develop advanced disease. In 2018, the FDA approved cemiplimab-rwlc as the first programmed cell death-1 (PD-1) monoclonal antibody for the treatment...

Full description

Bibliographic Details
Main Authors: Atsou, K. (Author), Ayers, D. (Author), Chen, C.-I (Author), Cope, S. (Author), Guyot, P. (Author), Keeping, S. (Author), Konidaris, G. (Author), Kuznik, A. (Author), Mojebi, A. (Author), Paul, E. (Author), Sasane, M. (Author), Xu, Y. (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
Online Access:View Fulltext in Publisher